CNBX Pharmaceuticals Inc. (CNBX)
OTCMKTS: CNBX · Delayed Price · USD
0.0100
+0.0040 (66.67%)
Jul 26, 2024, 4:00 PM EDT - Market closed
CNBX Pharmaceuticals Employees
CNBX Pharmaceuticals had 2 employees as of August 31, 2023. The number of employees decreased by 3 or -60.00% compared to the previous year.
Employees
2
Change (1Y)
-3
Growth (1Y)
-60.00%
Revenue / Employee
$270,120
Profits / Employee
-$604,084
Market Cap
311.11K
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
CNBX News
- 1 year ago - CNBX to Enter the Cancer Immunotherapy Market After Acquiring a Controlling Interest in TaGeza Biopharma - PRNewsWire
- 1 year ago - CNBX Files New PCT Patent Application For Cannabinoids-Based Neoadjuvant Cancer Therapy - PRNewsWire
- 1 year ago - CNBX Patent Application "Composition and Method for Treating Cancer with Cannabinoids" Enters National Phase in US and Israel - PRNewsWire
- 1 year ago - CNBX Peer-reviewed Study: "Possible Future Therapeutic Value" for CNBX Proprietary Drug Candidate - PRNewsWire
- 1 year ago - CNBX Pharmaceuticals Announces New Patent Granted in Australia - PRNewsWire
- 2 years ago - CNBX Pharmaceuticals Granted Patent in Hong Kong - PRNewsWire
- 2 years ago - Cannabics Pharmaceuticals Changes Name to CNBX Pharmaceuticals - PRNewsWire
- 2 years ago - CNBX Selects API Supplier Purisys to Support Planned IND Fillings and Phase I/II (a) Clinical Trials - PRNewsWire